This review found that patients with PCOS treated with GLP-1 receptor agonists, both as adjuvant therapy and monotherapy, had significant improvements in their anthropometric measurements, as well as biomarkers of insulin resistance. This evidence concerns the gene GLP1R and polycystic ovary syndrome.